Overview

Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:
0

Participant gender:
All

Summary

Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the pulmonary arteries (PAP) is high. PAH increases the risk of adverse events, including death, during and or after procedures. The severity of baseline PAH correlates with the incidence of major complications, such that those with PAP higher than their systemic blood pressure (SBP) had a 8 fold increased risk of complications. These children present for procedures where an acute exacerbation of their chronic illness-termed Pulmonary Hypertensive (PH)crisis, can occur, often resulting in death if not detected and managed expeditiously. Unfortunately there is little data and no consensus in the pediatric literature on how PH crisis should be managed. --------------------------------------------------------------------------------

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Stanford University

Treatments:

Arginine Vasopressin
Epinephrine
Epinephryl borate
Oxymetazoline
Phenylephrine
Racepinephrine
Vasopressins

Criteria

Inclusion Criteria:

- Patients presenting for cardiac catheterization procedure with a diagnosis of PAH
either by previous cardiac catheterization or echocardiography

Exclusion Criteria:

- Children presenting for cardiac catheterization who do not have PAH;

- Children with PAH but with intracardiac shunts